<DOC>
	<DOC>NCT00385255</DOC>
	<brief_summary>The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years. This study will also provide safety and immunogenicity data in a cohort of adults aged greater than or equal to 65 years.</brief_summary>
	<brief_title>Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<criteria>Healthy male or female adults aged between 19 to 64 years, inclusive for the primary cohort), or aged 65 years or older (for the exploratory cohort), at the time of vaccination. Administration of an influenza vaccine within six months prior to study entry Administration of a diphtheriatetanus (Td) booster within the previous 5 years. Administration of a Tdap vaccine at any time prior to study entry. Administration of any investigational or nonregistered drug or vaccine other than the study vaccines within 30 days preceding vaccination, or planned use during the entire study period. History of diphtheria and/or tetanus and/or pertussis disease. History of serious allergic reaction (e.g. anaphylaxis) following any other tetanus toxoid, diphtheria toxoid or pertussiscontaining vaccine or influenza vaccine or any component of the study vaccines.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Immunogenicity,</keyword>
	<keyword>Influenza</keyword>
	<keyword>Co-administration,</keyword>
	<keyword>Tdap,</keyword>
</DOC>